The effect of denosumab on RANKL signaling, inhibition of PTH-driven bone resorption and associated reduction of serum calcium levels makes it a useful tool to control severe hypercalcemia in patients with PHPT before surgery or if surgery is contraindicated for some reasons. This evidence concerns the gene TNFSF11 and Hypercalcemia.